Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections

Basit Öğe Kaydı
dc.authoridGüçLü, Ertuğrul/0000-0003-2860-2831
dc.authoridaltay, fatma aybala/0000-0002-7149-2968
dc.authoridOzturk-Engin, Derya/0000-0002-2566-7317
dc.authoridSezak, Nurbanu/0000-0001-9472-1340
dc.authoridAtaman Hatipoğlu, Çiğdem/0000-0002-1104-8232
dc.authoridbalkan, ilker inanc/0000-0002-8977-5931
dc.authoridKarabay, Oguz/0000-0003-1514-1685
dc.authorwosidOztoprak, Nefise/AAD-2679-2019
dc.authorwosidGüçLü, Ertuğrul/AAM-8247-2020
dc.authorwosidaltay, fatma aybala/AFP-3599-2022
dc.authorwosidOzturk-Engin, Derya/AFG-5927-2022
dc.authorwosidSezak, Nurbanu/JWA-2218-2024
dc.authorwosidAtaman Hatipoğlu, Çiğdem/AAA-4135-2021
dc.authorwosidbalkan, ilker inanc/AAI-1578-2019
dc.contributor.authorBatirel, A.
dc.contributor.authorBalkan, I. I.
dc.contributor.authorKarabay, O.
dc.contributor.authorAgalar, C.
dc.contributor.authorAkalin, S.
dc.contributor.authorAlici, O.
dc.contributor.authorAlp, E.
dc.date.accessioned2024-06-12T11:17:36Z
dc.date.available2024-06-12T11:17:36Z
dc.date.issued2014
dc.departmentTrakya Üniversitesien_US
dc.description23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) -- APR 30, 2013 -- Berlin, GERMANYen_US
dc.description.abstractThe purpose of this investigation was to compare the efficacy of colistin-based therapies in extremely drug-resistant Acinetobacter spp. bloodstream infections (XDR-ABSI). A retrospective study was conducted in 27 tertiary-care centers from January 2009 to August 2012. The primary end-point was 14-day survival, and the secondary end-points were clinical and microbiological outcomes. Thirty-six and 214 patients [102 (47.7 %): colistin-carbapenem (CC), 69 (32.2 %): colistin-sulbactam (CS), and 43 (20.1 %: tigecycline): colistin with other agent (CO)] received colistin monotherapy and colistin-based combinations, respectively. Rates of complete response/cure and 14-day survival were relatively higher, and microbiological eradication was significantly higher in the combination group. Also, the in-hospital mortality rate was significantly lower in the combination group. No significant difference was found in the clinical (p = 0.97) and microbiological (p = 0.92) outcomes and 14-day survival rates (p = 0.79) between the three combination groups. Neither the timing of initial effective treatment nor the presence of any concomitant infection was significant between the three groups (p > 0.05) and also for 14-day survival (p > 0.05). Higher Pitt bacteremia score (PBS), Acute Physiology and Chronic Health Evaluation II (APACHE II) score, Charlson comorbidity index (CCI), and prolonged hospital and intensive care unit (ICU) stay before XDR-ABSI were significant risk factors for 14-day mortality (p = 0.02, p = 0.0001, p = 0.0001, p = 0.02, and p = 0.01, respectively). In the multivariable analysis, PBS, age, and duration of ICU stay were independent risk factors for 14-day mortality (p < 0.0001, p < 0.0001, and p = 0.001, respectively). Colistin-based combination therapy resulted in significantly higher microbiological eradication rates, relatively higher cure and 14-day survival rates, and lower in-hospital mortality compared to colistin monotherapy. CC, CS, and CO combinations for XDR-ABSI did not reveal significant differences with respect to 14-day survival and clinical or microbiological outcome before and after propensity score matching (PSM). PBS, age, and length of ICU stay were independent risk factors for 14-day mortality.en_US
dc.identifier.doi10.1007/s10096-014-2070-6
dc.identifier.endpage1322en_US
dc.identifier.issn0934-9723
dc.identifier.issn1435-4373
dc.identifier.issue8en_US
dc.identifier.pmid24532009en_US
dc.identifier.scopus2-s2.0-84903819291en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1311en_US
dc.identifier.urihttps://doi.org/10.1007/s10096-014-2070-6
dc.identifier.urihttps://hdl.handle.net/20.500.14551/24776
dc.identifier.volume33en_US
dc.identifier.wosWOS:000338723600006en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofEuropean Journal Of Clinical Microbiology & Infectious Diseasesen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAppropriate Antimicrobial Therapyen_US
dc.subjectIn-Vitroen_US
dc.subjectAntibiotic Combinationsen_US
dc.subjectPseudomonas-Aeruginosaen_US
dc.subjectSerious Infectionsen_US
dc.subjectApache-Iien_US
dc.subjectBacteremiaen_US
dc.subjectRifampicinen_US
dc.subjectPneumoniaen_US
dc.subjectMortalityen_US
dc.titleComparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infectionsen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu